

June 10, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Disclosure of Related Party Transactions for the half year ended 31st March, 2022

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions for the half year / six months ended 31st March, 2022.

The same is also being made available on the website of the Company at www.glenmarkpharma.com

Thanking you.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber

**Company Secretary & Compliance Officer** 

Encl: As above

					Disclosure of Pole	ted Party Transactions for the half year ended 31st March 20	177									₹ in Millio
					Disclosure of Reia	led Party Transactions for the nam year ended 51st Warch 20	122	I			Additional disc	losure of related p	arty transactions -	applicable only in ca	se the related	party transaction relate
											to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary.					
											These details need to be disclosed only once, during the reporting period when such transaction was undertaken.					
	Details of the party entering into the transaction  Details of the counterparty			rparty		Wall a state of			es are due to is a result of the			Details of the loans, inter-corporate deposits, advances or investme				
							Value of the related party		transaction			ancial indebtednes	5			
Sr. No.						Type of related party transaction	transaction a				is incurred to make or give loans, inter-corporate deposits,					
						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	approved by the audit	reporting			advances or investments					
							committee	period			Nature of		Nature (loan/			Purpose for which t
					Relationship of the counterparty with the lister	1			Opening	Closing	indebtedness		advance/ inter-	Interest _	Secured/	funds will be utilised
	Name	PAN	Name	PAN	entity				balance (01.10.2021)	balance (31.03.2022)	(loan/issuance	e Cost Tenure	corporate	Rate (%)	unsecured	by the ultimate
									(01.10.2021)	(31.03.2022)	of debt/ any other etc.)		deposit/ investment			recipient of funds (end-usage)
1	Glenmark Pharmaceuticals Limited		Ichnos Sciences SA		Wholly Owned Subsidiary	Sale of materials & services	63.11	1 63.1	11							+
2	Glenmark Pharmaceuticals Limited		Glenmark Farmaceutica Ltda.		Wholly Owned Subsidiary	Sale of materials & services	483.94									
3 4	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Phillipines Inc. Glenmark Impex L.L.C.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of materials & services Sale of materials & services	205.91	1 205.9	_			+ +	1			+
5	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals South Africa (Pty) Ltd.		Wholly Owned Subsidiary	Sale of materials & services	103.69	103.6	59							
6 7	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Peru SAC. Glenmark Pharmaceuticals (Thailand) Co. Ltd.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of materials & services Sale of materials & services	14.34		_							_
8	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Kenya Ltd.		Wholly Owned Subsidiary	Sale of materials & services	300.09	300.0	_							
9 10	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Colombia Ltda. Glenmark Pharmaceuticals Mexico, S.A. DE C.V.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of materials & services Sale of materials & services	13.48									+
11	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Mexico, 3.A. BE C.V. Glenmark Pharmaceuticals Malaysia Sdn Bhd.		Wholly Owned Subsidiary	Sale of materials & services	155.80	155.8								+
12	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Inc.	-	Wholly Owned Subsidiary	Sale of materials & services	7,581.76	7,581.7	_							
13 14	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd.	-	Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of materials & services Sale of materials & services	1,076.18 515.63	3 1,076.3 515.6	_							+
15	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Ecuador		Wholly Owned Subsidiary	Sale of materials & services	22.67	7 22.6	57							1
16 17	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Glenmark Ukrain LLC Glenmark Pharmaceuticals Canada Inc.	-	Wholly Owned Subsidiary Wholly Owned Subsidiary	Sale of materials & services Sale of materials & services	336.3 <sup>4</sup> 35.99			+	+	+ + -	+	+ +	+	+
18	Glenmark Pharmaceuticals Limited		Glenmark Specialty S.A.		Wholly Owned Subsidiary	Sale of materials & services	1,537.68	1,537.6	58							
19 20	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Arznimittel GmBH Glenmark Lifesciences Ltd.	_	Wholly Owned Subsidiary	Sale of materials & services Sale of materials & services	0.00 4,912.60			1		+ + -	ļ	<b> </b>	-	+
21	Glenmark Pharmaceuticals Limited	1	Ichnos Sciences SA		Subsidiary Wholly Owned Subsidiary	Other Operating Income	4,912.60		_	<u> </u>			<u> </u>			<u>+-</u>
22	Glenmark Pharmaceuticals Limited		Ichnos Sciences Biotherapeutics S.A		Wholly Owned Subsidiary	Other Operating Income	6.27	7 6.2	27							I
23	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Other Operating Income Purchase of materials & services(inclusive reimbursements)	249.31 552.36	249.3				+ +	1			+
25	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals FZE.		Wholly Owned Subsidiary	Purchase of materials & services(inclusive reimbursements)	109.06	109.0	06							
26 27	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Farmaceutica Ltda. Glenmark Pharmaceuticals Europe Ltd.	-	Wholly Owned Subsidiary Wholly Owned Subsidiary	Purchase of materials & services(inclusive reimbursements)  Purchase of materials & services(inclusive reimbursements)	111.87 172.43	7 111.8 3 172.4								_
28	Glenmark Pharmaceuticals Limited		Glenmark Impex L.L.C.		Wholly Owned Subsidiary	Purchase of materials & services (inclusive reimbursements)	489.79	489.7	_							1
29 30	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals s.r.o.		Wholly Owned Subsidiary	Purchase of materials & services(inclusive reimbursements)	11.36		_							1
31	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Canada Inc. Glenmark Pharmaceuticals Kenya Ltd.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Purchase of materials & services(inclusive reimbursements)  Purchase of materials & services(inclusive reimbursements)	106.24 5.33	1 106.2	_							_
32	Glenmark Pharmaceuticals Limited		Glenmark Singapore Pte Ltd.		Wholly Owned Subsidiary	Purchase of materials & services(inclusive reimbursements)	4.48									
33	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Ukraine LLC Glenmark Lifesciences Ltd.		Wholly Owned Subsidiary Subsidiary	Purchase of materials & services(inclusive reimbursements)  Purchase of materials & services(inclusive reimbursements)	4,912.60	1 12.8	_			+ +	1			+
35	Glenmark Pharmaceuticals Limited		Ichnos Sciences Inc.		Wholly Owned Subsidiary	Purchase of materials & services(inclusive reimbursements)	2.73		_							
36 37	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Trilegal Glenmark Pharmaceuticals Inc.	+	Other related parties Wholly Owned Subsidiary	Purchase of services Purchase of Tangibles/Capex	15.00					+ +				+
38	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Colombia Ltda.		Wholly Owned Subsidiary	Investment in share capital	62.42						Investment	NA NA	Unsecured	Business Purpose
39 40	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Mexico, S.A. DE C.V. Glenmark Pharmaceuticals Peru SAC.		Wholly Owned Subsidiary Wholly Owned Subsidiary	Share Application Money Share Application Money	91.71		_							
41	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Colombia Ltda.		Wholly Owned Subsidiary	Share Application Money	11.38	3 11.3								+
42 43	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Holding S A	-	Wholly Owned Subsidiary Wholly Owned Subsidiary	Share Application Money	56.03 5,727.30	56.0	_				Loan	4.50% 5 Years	Unsecured	Business Purpose
44	Glenmark Pharmaceuticals Limited		Glenmark Holding S.A. Glenmark Holding S.A.		Wholly Owned Subsidiary  Wholly Owned Subsidiary	Loan given Interest income	1,749.51	1 1,749.5	_				LOAN	4.50% 5 fears	Unsecured	Business Purpose
45	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals (Nigeria) Ltd.		Wholly Owned Subsidiary	Interest income	2.51	1 2.5								
46	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Kenya Ltd. Glenmark Pharmaceuticals (Thailand) Co Ltd.	+	Wholly Owned Subsidiary Wholly Owned Subsidiary	Interest income Interest income	6.72 0.27									+
48			Glenmark Pharmaceuticals Egypt S.A.E.		Wholly Owned Subsidiary	Interest income	5.95	5.9	95							
49 50	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Holding S.A. Glenmark Holding S.A.	-	Wholly Owned Subsidiary Wholly Owned Subsidiary	Loan given to subsidiary converted into Investment Other Income	15,368.32 13.20	15,368.3				+	Investment	NA NA	Unsecured	Business Purpose
51	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals s.r.o.		Wholly Owned Subsidiary	Other Income	0.64	1 0.6	54							
52 53	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Inc. Glenmark Lifescience Limited		Wholly Owned Subsidiary	Other Income Other Income	12.53									+
54			Glenmark Litescience Limited Glenmark Foundation		Subsidiary Other related parties	Contribution incurred for CSR activities	1,065.80			<u> </u>	<u> </u>				<u> </u>	<u> </u>
55	Glenmark Pharmaceuticals Limited		Glenmark Aquatic Foundation		Other related parties	Contribution incurred for CSR activities	100.00	3.6								4
56 57	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	+	Mr. Glenn Saldanha Mrs. Cherylann Pinto		KMP	Remuneration paid Remuneration paid	80.15 25.70	80.1		+	+	+ +	+	+ + -	+	+
58	Glenmark Pharmaceuticals Limited		Mr. V S Mani		KMP	Remuneration paid	24.69	24.6	59							1
59 60		+	Mr. Harish Kuber Mrs. Blanche Saldanha	+	KMP Non Executive - Non Independent Director	Remuneration paid Sitting Fees	0.10			1	+	+ +	+	+ + +	1	+
61	Glenmark Pharmaceuticals Limited		Mr. D.R. Mehta		Independent Director	Sitting Fees	1.00	1.0	00							<b></b>
62 63	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Mr. Rajesh Desai Mr. Brian Tempest	+	Independent Director Independent Director	Sitting Fees Sitting Fees	0.80			+	+	+ + -	+	+ +	-	+
64	Glenmark Pharmaceuticals Limited		Mr. Bernard Munos		Independent Director	Sitting Fees	0.20	0.2	20							1
65 66	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited		Mrs. Sona Saira Ramasastry Mr. Dipankar Bhattacharjee	_	Independent Director Independent Director	Sitting Fees Sitting Fees	0.60			1	1		1	<b> </b>	_	+
67	Glenmark Pharmaceuticals Limited	1	Glenmark Arzneimittel GmbH	1	Wholly Owned Subsidiary	Sitting Fees Receivable	0.40	0.4	11.6	3 0.0	0					<u>+</u>
68			Glenmark Farmaceutica Ltda.		Wholly Owned Subsidiary	Receivable			1,239.7		_					
69 70	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	+	Glenmark Philippines Inc. Ichnos Sciences SA	+	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Receivable	+		81.8 31.8			+ + -	+	+ + +	1	+
71	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals S.A.		Wholly Owned Subsidiary	Receivable			1.3	0 1.3	3					
72 73	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	+	Glenmark Holding S.A. Ichnos Sciences Biotherapeutics S.A	+	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Receivable	+	1	77,444.9		_	+	+	+	-	+
74	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals (Nigeria) Ltd.		Wholly Owned Subsidiary	Receivable			385.9	7 395.4	7					1
75 76	Glenmark Pharmaceuticals Limited		Glenmark Impex L.L.C.		Wholly Owned Subsidiary	Receivable			352.1			+			-	+
76 77	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	1	Glenmark Pharmaceuticals South Africa (Pty) Ltd. Glenmark Pharmaceuticals FZE.	1	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Payable			357.2 320.8						$\pm$	<u>+</u>
78	Glenmark Pharmaceuticals Limited		Glenmark Generics SA.		Wholly Owned Subsidiary	Receivable			0.4	8 0.4	_					1
79 80	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	+	Glenmark Pharmaceuticals Venezuela. C.A Glenmark Pharmaceuticals Malaysia Sdn.Bhd.	+	Wholly Owned Subsidiary Wholly Owned Subsidiary	Receivable Receivable	+	1	1,558.2 650.4		_	+ +	+	+ + +	1	+
81	Glenmark Pharmaceuticals Limited		Glenmark Pharmaceuticals Peru SAC.		Wholly Owned Subsidiary	Receivable			88.8	5 49.5	6					
82 83	Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited	-	Glenmark Pharmaceuticals Europe Ltd. Glenmark Pharmaceuticals Inc.	-	Wholly Owned Subsidiary Wholly Owned Subsidiary	Payable Receivable		1	1,474.1 6,718.9			+ + -	1	<del>                                     </del>	1	<del></del>
84	Glenmark Pharmaceuticals Limited	+	Glenmark Pharmaceuticals Inc. Glenmark Pharmaceuticals s.r.o.	-	Wholly Owned Subsidiary  Wholly Owned Subsidiary	Receivable		1	1,299.3		_	+ + -	+	<del>                                     </del>	1	+

85 Glenmark Pharmaceuticals Limited	Glenmark Therapeutics Inc.	Wholly Owned Subsidiary	Receivable	3.94	3.94			
86 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals SK, s.r.o.	Wholly Owned Subsidiary	Payable	0.01	0.01			
87 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals SP Zoo	Wholly Owned Subsidiary	Payable	0.15	0.15			
88 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals (Thailand) Co. Ltd.	Wholly Owned Subsidiary	Receivable	43.23	24.39			
89 Glenmark Pharmaceuticals Limited	Glenmark Uruguay S.A.	Wholly Owned Subsidiary	Payable	741.18	754.98			
90 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Colombia Ltda.	Wholly Owned Subsidiary	Receivable	59.47	47.60			
91 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Kenya Ltd.	Wholly Owned Subsidiary	Receivable	985.93	1,010.67			
92 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Mexico S.A. DE C.V.	Wholly Owned Subsidiary	Receivable	245.73	200.13			
93 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Egypt S.A.E.	Wholly Owned Subsidiary	Receivable	143.98	152.65			
94 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Canada Inc.	Wholly Owned Subsidiary	Receivable	378.88	173.71			
95 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals B.V.	Wholly Owned Subsidiary	Payable	0.01	0.01			
96 Glenmark Pharmaceuticals Limited	Glenmark Specialty S.A.	Wholly Owned Subsidiary	Receivable	3,488.55	3,587.02			
97 Glenmark Pharmaceuticals Limited	Glenmark Ukraine LLC	Wholly Owned Subsidiary	Receivable	270.45	314.04			
98 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Ecuador S.A.	Wholly Owned Subsidiary	Receivable	127.15	84.74			
99 Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Singapore	Wholly Owned Subsidiary	Payable	52.06	49.69			
100 Glenmark Pharmaceuticals Limited	Ichnos Sciences Inc.	Wholly Owned Subsidiary	Receivable	2.69	5.48			
101 Glenmark Pharmaceuticals Limited	Glenmark Lifesciences Ltd.	Subsidiary	Payable	2,656.46	2,697.43			

- Notes:

  All Related Party Transactions entered during the period were in ordinary course of the business and on arm's length basis.

  Expenses for Defined Benefit Plans and Compensated Absences are provided on actuarial basis for the Company as a whole, the amounts pertaining to Key Managerial Personnel is not included.

  Share Based Payment Expenses pertaining to Key Manaerial Personnel Is not included.

  Balances have been aggregated entity wise for all type of transactions and shown as net receivable/(payable)

  As per the guidance note for disclosure of related party transactions dated 25th April, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure.

  The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors, as applicable, for financial year 2021-22.